薬剤性内分泌障害診療マニュアル

出版社： 診断と治療社
著者：
発行日： 2022-09-09
分野： 臨床医学：内科  >  内分泌/代謝
ISBN： 9784787824936
電子書籍版： 2022-09-09 （電子版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,950 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,950 円(税込)

購入する

商品紹介

近年，薬剤性の内分泌障害の経験が増加し，注目が集まっている．本書は，単に薬剤による副作用のまとめにとどまらず，薬剤による内分泌障害の特徴や早期診断・治療法を，①内分泌障害からそれを引き起こす薬剤，②薬剤の薬効別分類から引き起こされる内分泌障害，の二方向から解説を行い，実診療で検索しやすくしてある．
内分泌代謝の専門医のみならず，様々な専門分野の臨床医にとって，副作用の早期診断と適切な対処に役立つ1冊．

目次

  • 総　　論（代表的な内分泌障害別）
    Ａ　下垂体前葉機能低下症をきたす薬剤
    　1　内分泌系薬
    　2　抗悪性腫瘍薬
    Ｂ　高プロラクチン血症をきたす薬剤
    　1　精神神経用剤
    　2　消化器官用剤
    　3　循環器官用剤
    　4　内分泌系薬
    Ｃ　抗利尿ホルモン不適切分泌症候群をきたす薬剤
    　1　精神神経用剤
    　2　消化器官用剤
    　3　循環器官用剤
    　4　代謝系薬
    　5　抗悪性腫瘍薬
    　6　コメント
    Ｄ　尿崩症をきたす薬剤
    　1　精神神経用剤
    　2　内分泌系薬
    　3　代謝系薬
    　4　感染症薬
    　5　抗悪性腫瘍薬
    Ｅ　甲状腺機能異常をきたす薬剤
    　1　精神神経用剤
    　2　消化器官用剤
    　3　循環器官用剤
    　4　内分泌系薬
    　5　代謝系薬
    　6　感染症薬
    　7　免疫抑制薬
    　8　抗悪性腫瘍薬
    Ｆ　副腎皮質機能低下症をきたす薬剤
    　1　精神神経用剤
    　2　感染症薬
    　3　代謝系薬
    　4　抗悪性腫瘍薬
    Ｇ　偽アルドステロン症をきたす薬剤

    各　　論（薬効別）
    Ａ　精神神経用剤
    Ｂ　消化器官用剤
    Ｃ　循環器官用剤
    Ｄ　内分泌系薬
    Ｅ　代謝系薬
    Ｆ　感染症薬
    Ｇ　免疫抑制薬
    Ｈ　抗悪性腫瘍薬
    　1　分子標的治療薬
    　2　免疫チェックポイント阻害薬
    　3　その他の薬剤
    Ｉ　漢方薬・グリチルリチン製剤

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論 ( 代表的な内分泌障害別 )

P.4 掲載の参考文献
1) 日本内分泌学会, ほか : 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日内分泌会誌 2015 ; 91 (Suppl) : 1-78.
 
2) 柴田洋孝 : 副腎不全の原因と分類. 日内会誌 2008 ; 97 : 702-707.
 
3) Kobayashi T, et al. : Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma : a prospective study. J Immunother Cancer 2020 ; 8 : e000779.
PubMed
4) 日本内分泌学会 (編) : 免疫チェックポイント阻害薬による内分泌障害の診療ガイドライン. 日内分泌会誌 2018 ; 94 (Suppl) : 1-11.
 
5) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班, ほか (編) : 間脳下垂体機能障害の診断と治療の手引き (平成30年度改訂). 日内分泌会誌 2019 ; 95 (Suppl) : 1-60.
 
6) 日本内分泌学会, ほか : 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日内分泌会誌 2015 ; 91 (Suppl) : 1-78.
 
P.9 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班, ほか編 : 間脳下垂体機能障害の診断と治療の手引き (平成30年度改訂). 日内分泌会誌 2019 ; 95 (Suppl) : 1-60.
 
2) Molitch ME : Drugs and prolactin. Pituitary 2008 ; 11 : 209-218.
PubMed
3) Samperi I, et al. : Hyperprolactinaemia. J Clin Med 2019 ; 8 : 2203.
PubMed
4) Melmed S, et al. Diagnosis and treatment of hyperprolactinemia : an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011 ; 96 : 273-288.
PubMed
5) Jones RB, et al. : Plasma prolactin concentrations in normal subjects and depressive patients following oral clomipramine. Postgrad Med J. 1977 ; 53 Suppl 4 : 166-171.
 
P.14 掲載の参考文献
藤沢治樹, ほか : 薬剤性低ナトリウム血症. 内分泌糖尿代謝内科 2019 ; 49 : 125-128.
 
Liamis G, et al. : A review of drug-induced hyponatremia. Am J Kidney Dis 2008 ; 52 : 144-153.
PubMed
Shepshelovich D, et al. : Medication-induced SIADH : distribution and characterization according to medication class. Br J Clin Pharmacol 2017 ; 83 : 1801-1807.
PubMed
Ware JS, et al. : Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia. J Clin Invest 2017 ; 127 : 3367-3374.
PubMed
Jacob S, et al. : Hyponatremia associated with selective serotoninreuptake inhibitors in older adults. Ann Pharmacother 2006 ; 40 : 1618-1622.
PubMed
Sailer CO, et al. : Characteristics and outcomes of patients with profound hyponatraemia due to primary primary polydipsia. Clin Endocrinol (Oxf) 2017 ; 87 : 492-499.
PubMed
Falhammar H, et al. : Associations of proton pump inhibitors and hospitalization due to hyponatremia : A population-based casecontrol study. Eur J Intern Med 2019 ; 59 : 65-69.
 
Liamis G, et al. : Hyponatremia-Inducing Drugs. Front Horm Res 2019 ; 52 : 167-177.
PubMed
P.27 掲載の参考文献
1) Ott M, et al. : Lithium treatment, nephrogenic diabetes insipidus and the risk of hypernatraemia : a retrospective cohort study. Ther Adv Psychopharmacol 2019 ; 9 : 1-11.
 
2) Garofeanu CG, et al. : Causes of reversible nephrogenic diabetes insipidus : a systematic review. Am J Kidney Dis 2005 ; 45 : 626-637.
PubMed
3) L'Heude M, et al. : Nephrogenic diabetes insipidus associated with prolonged sedation with sevoflurane in the intensive care unit. Br J Anaesth 2019 ; 122 : e73-e75.
PubMed
4) Honore PM, et al. : Sevoflurane and nephrogenic diabetes insipidus on the rise : copeptin to the rescue? Crit Care 2019 ; 23 : 304.
 
5) Gaffar S, et al. : A case of central diabetes insipidus after ketamine infusion during an external to internal carotid artery bypass. J Clin Anesth 2017 ; 36 : 72-75.
 
6) Kataria V, et al. : Ketamine-induced diabetes insipidus. J Pain Palliat Care Pharmacother 2018 ; 32 : 165-169.
PubMed
7) Herity LB, et al. : Delayed onset of central diabetes insipidus with ketamine sedation : A report of 2 cases. J Pharm Pract 2021 ; 34 : 314-318.
 
8) Bendz H, et al. : Drug-induced diabetes insipidus : incidence, prevention and management. Drug Saf 1999 ; 21 : 449-456.
PubMed
9) Chen M, et al. : Dexamethasone increases aquaporin-2 protein expression in ex vivo inner medullary collecting duct suspensions. Front Physiol 2015 ; 6 : 310.
PubMed
10) Usalan C, et al. : Hypernatraemia and polyuria due to high-dose colchicine in a suicidal patient. Nephrol Dial Transplant 1999 ; 14 : 1556-1557.
 
11) Dousa TP, et al. : Effects of colchicine and vinblastine on the cellular action of vasopressin in mammalian kidney. A possible role of microtubules. J Clin Invest 1974 ; 54 : 252-262.
 
12) Singer I, et al. : Demeclocycline-induced nephrogenic diabetes insipidus. In-vivo and in-vitro studies. Ann Intern Med 1973 ; 79 : 679-683.
PubMed
13) 日本腎臓学会マニュアル作成委員会, ほか : 重篤副作用疾患別対応マニュアル 腎性尿崩症 平成23年3月 (平成30年6月改定). 厚生労働省, 2018. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1e45.pdf (2022年5月20日アクセス)
 
14) Spath-Schwalbe E, et al. : Successful use of liposomal amphotericin B in a case of amphotericin B-induced nephrogenic diabetes insipidus. Clin Infect Dis 1999 ; 28 : 680-681.
 
15) Vukicevic T, et al. : Fluconazole increases osmotic water transport in renal collecting duct through effects on aquaporin-2 trafficking. J Am Soc Nephrol 2019 ; 30 : 795-810.
PubMed
16) Karras A, et al. : Tenofovir-related nephrotoxicity in human immunodeficiency virus infected patients : Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003 ; 36 : 1070-1073.
PubMed
17) Rollot F, et al. : Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome : the role of lopinavir-ritonavirdidanosine. Clin Infect Dis 2003 ; 37 : e174-e176.
 
18) Pajvani U, et al. : Diabetes insipidus associated with hemophagocytic lymphohistiocytosis : first case report. Endocr Pract 2011 ; 17 : e118-e122.
PubMed
19) 樋口雄一, ほか : インフルエンザワクチンが契機と考えられた中枢性尿崩症の一例. 日内分泌会誌 2020 ; 96 : 498.
Medical*Online
20) Ingemi AI, et al. : Fanconi's syndrome and nephrogenic diabetes insipidus in an adult treated with ifosfamide. Pharmacotherapy 2012 ; 32 : e12-e16.
 
21) Leem AY, et al. : Ifosfamide-induced Fanconi syndrome with diabetes insipidus. Korean J Intern Med 2014 ; 29 : 246-249.
PubMed
22) Gunawan F, et al. : Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies. Endocrinol Diabetes Metab Case Rep 2018 ; 17-0146.
PubMed
23) Fosci M, et al. : Diabetes insipidus secondary to nivolumab-induced neurohypophysitis and pituitary metastasis. Endocrinol Diabetes Metab Case Rep 2021 ; 20-0123.
PubMed
24) Deligiorgi M, et al. : Central diabetes insipidus related to antiprogrammed cell-death 1 protein active immunotherapy. Int Immunopharmacol 2020 ; 83 : 106427.
PubMed
25) Bai X, et al. : Immune checkpoint inhibitor-associated pituitary adverse events : an observational, retrospective, disproportionality study. J Endocrinol Invest 2020 ; 43 : 1473-1483.
PubMed
P.46 掲載の参考文献
1) 社団法人日本甲状腺学会マニュアル作成委員会, ほか : 重篤副作用疾患別対応マニュアル 甲状腺機能低下症 平成21年5月 (令和4年2月改定). 厚生労働省, 2022. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1d37.pdf (2022年5月17日アクセス)
 
2) Czarnocka A, et al. : Effect of lithium carbonate on the function of the thyroid gland : mechanism of action and clinical implications. J Physiol Pharmacol 2020 ; 71 : 191-199.
 
3) Caye A, et al. : The impact of selective serotonin reuptake inhibitors on the thyroid function among patients with major depressive disorder : A systematic review and meta-analysis. Eur Neuropsychopharmacol 2020 ; 33 : 139-145.
PubMed
4) Eker SS, et al. : Reversible escitalopram-induced hypothyroidism. Gen Hosp Psychiatry 2010 ; 32 : 559.e5-559.e7.
 
5) 野村惠巳子, ほか : 甲状腺機能低下症. 日臨 2019 ; 77 : 460-466.
Medical*Online
6) Gungor O, et al. : The effect of antiepileptic drugs on thyroid hormonal function : valproic acid and phenobarbital. Acta Neurol Belg 2020 ; 120 : 615-619.
PubMed
7) 社団法人日本甲状腺学会マニュアル作成委員会, ほか : 重篤副作用疾患別対応マニュアル 甲状腺中毒症 平成21年5月 (令和4年2月改定). 厚生労働省, 2022. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1d33.pdf (2022年5月20日アクセス)
 
8) 藤原雄太, ほか : アミオダロン服用中の甲状腺機能に関する検討. 心臓 2013 ; 45 : 1101-1109.
Medical*Online
9) 日本甲状腺学会編 : アミオダロン誘発性甲状腺中毒症の治療. In : バセドウ病治療ガイドライン 2019, 南江堂, 2019 : 109-111.
 
10) Haugen BR : Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab 2009 ; 23 : 793-800.
PubMed
11) Feek CM, et al. : Influence of thyroid status on dopaminergic inhibition of thyrotropin and prolactin secretion : evidence for an additional feedback mechanism in the control of thyroid hormone secretion. J Clin Endocrinol Metab 1980 ; 51 : 585-589.
PubMed
12) Lee E, et al. : Effect of acute high dose dobutamine administration on serum thyrotropin (TSH). Clin Endocrinol (Oxf) 1999 ; 50 : 487-492.
PubMed
13) Amino N, et al. : Possible induction of Graves' disease and painless thyroiditis by gonadotropin-releasing hormone analogues. Thyroid 2003 ; 13 : 815-818.
PubMed
14) Furr BJ : Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogues, Zoladex. Horm Res 1989 ; 32 (Suppl) : 86-92.
 
15) 網野信行, ほか : 自己免疫性甲状腺疾患の増悪因子. 診断と治療 2005 ; 93 : 1128-1133.
Medical*Online
16) Arafah BM : Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001 ; 344 : 1743-1749.
PubMed
17) Chetkowski RJ, et al. : Biologic effects of transdermal estradiol. N Engl J Med 1986 ; 314 : 1615-1620.
PubMed
18) Steingold KA, et al. : Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. J Clin Endocrinol Metab 1991 ; 73 : 275-280.
PubMed
19) Mandel SJ, et al. : Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 1990 ; 323 : 91-96.
PubMed
20) Li D, et al. : Changes in thyroid function during controlled ovarian hyperstimulation (COH) and its impact on assisted reproduction technology (ART) outcomes : a systematic review and meta*analysis. J Assist Reprod Genet 2021 ; 38 : 2227-2235.
PubMed
21) Brabant A, et al. : The role of glucocorticoids in the regulation of thyrotropin. Acta Endocrinol (Copenh) 1989 ; 121 : 95-100.
PubMed
22) Nicoloff JT, et al. : The role of glucocorticoids in the regulation of thyroid function in man. J Clin Invest 1970 ; 49 : 1922-1929.
 
23) Baloch Z, et al. : Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003 ; 13 : 3-126.
PubMed
24) Itoh S, et al. : Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. Life Sci 1988 ; 42 : 2691-2699.
PubMed
25) Colao A, et al. : Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. Eur J Endocrinol 1995 ; 133 : 189-194.
PubMed
26) Freda PU : Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002 ; 87 : 3013-3018.
PubMed
27) Harmon SM, et al. : Levothyroxine-cholestyramine interaction reemphasized. Ann Intern Med 1991 ; 115 : 658-659.
PubMed
28) Northcutt RC, et al. : The influence of cholestyramine on thyroxine absorption. JAMA 1969 ; 208 : 1857-1861.
PubMed
29) Shakir KM, et al. : The use of bile acid sequestrants to lower serum thyroid hormones in iatrogenic hyperthyroidism. Ann Intern Med 1993 ; 118 : 112-113.
PubMed
30) 日本小児科学会, ほか (編) : 小児家族性高コレステロール血症診療ガイド 2017. 日本動脈硬化学会. 2017.
 
31) Mamby CC, et al. : Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J Clin Oncol 1995 ; 13 : 854-857.
PubMed
32) Ceresini G, et al. : A one-year follow-up on the effects of raloxifene on thyroid function in postmenopausal women. Menopause 2004 ; 11 : 176-179.
PubMed
33) Siraj ES, et al. : Raloxifene causing malabsorption of levothyroxine. Arch Intern Med 2003 ; 163 : 1367-1370.
PubMed
34) Garwood CL, et al. : Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene. Pharmacotherapy 2006 ; 26 : 881-885.
PubMed
35) Singh N, et al. : Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000 ; 283 : 2822-2825.
PubMed
36) Diskin CJ, et al. : Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement. Int Urol Nephrol 2007 ; 39 : 599-602.
PubMed
37) Mizutani H, et al. : Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS) -induced hypothyroidism. Kekkaku 2001 ; 76 : 667-672.
PubMed
38) Takasu N, et al. : Rifampin-induced hypothyroidism. J Endocrinol Invest 2006 ; 29 : 645-649.
PubMed
39) Prummel MF, et al. : Interferon-alpha and autoimmune thyroid disease. Thyroid 2003 ; 13 : 547-551.
PubMed
40) Carella C, et al. : The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002 ; 146 : 743-749.
 
41) Shen L, et al. : Thyroid dysfunction during interferon alpha therapy for chronic hepatitis C. Clin Nucl Med 2005 ; 30 : 546-547.
PubMed
42) Tran HA, et al. : Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response : a meta-analysis. J Gastroenterol Hepatol 2009 ; 24 : 1163-1168.
PubMed
43) Nair Kesavachandran C, et al. : Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients : a systematic review based analysis. PLoS One 2013 ; 8 : e55364.
PubMed
44) Chen F, et al. : Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore) 2005 ; 84 : 98-106.
PubMed
45) Muller I, et al. : 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy. Eur Thyroid J 2019 ; 8 : 173-185.
PubMed
46) Andrade LJ, et al. : A meta-analysis of patients with chronic hepatitis C treated with interferon-alpha to determine the risk of autoimmune thyroiditis. Acta Gastroenterol Latinoam 2011 ; 41 : 104-110.
PubMed
47) Nadeem A, et al. : Interferon-alpha induced and ribavirin induced thyroid dysfunction in patients with chronic hepatitis C. Hepat Mon 2010 ; 10 : 132-140.
PubMed
48) Narciso-Schiavon JL, et al. : Autoantibodies in chronic hepatitis C : A clinical perspective. World J Hepatol 2015 ; 7 : 1074-1085.
PubMed
49) Shen Y, et al. : Thyroid Disturbance in Patients with Chronic Hepatitis C Infection : A Systematic Review and Meta-analysis. J Gastrointestin Liver Dis 2016 ; 25 : 227-234.
PubMed
50) Krouse RS, et al. : Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 1995 ; 18 : 272-278.
PubMed
51) Torino F, et al. : Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid 2013 ; 23 : 1345-1366.
PubMed
52) Weijl NI, et al. : Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993 ; 11 : 1376-1383.
PubMed
53) Atkins MB, et al. : Hypothyroidism af ter t reatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988 ; 318 : 1557-1563.
 
54) Curti B, et al. : Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events : data from the PROCLAIMSM registry. J Immunother Cancer 2017 ; 5 : 102.
PubMed
55) Chang LS, et al. : Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev 2019 ; 40 : 17-65.
PubMed
56) Muir CA, et al. : Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid 2020 ; 30 : 1458-1469.
PubMed
57) Barroso-Sousa R, et al. : Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens : A Systematic Review and Meta-analysis. JAMA oncology 2018 ; 4 : 173-182.
PubMed
58) Yamauchi I, et al. : Incidence, features, and prognosis of immune related adverse events involving the thyroid gland induced by nivolumab. PLoS one 2019 ; 14 : e0216954.
PubMed
59) Caturegli P, et al. : Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade : Insights into Pathogenesis from an Autopsy Series. Am J Pathol 2016 ; 186 : 3225-3235.
PubMed
60) Desai J, et al. : Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006 ; 145 : 660-664.
PubMed
61) Miyake H,et al. : Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib : a prospective evaluation. Urol Oncol 2010 ; 28 : 515-519.
PubMed
62) Makita N, et al. : Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 2010 ; 20 : 323-326.
PubMed
63) Makita N, et al. : Tyrosine kinase inhibitor-induced thyroid disorders : a review and hypothesis. Thyroid 2013 ; 23 : 151-159.
PubMed
64) Abdulrahman RM, et al. : Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 2010 ; 95 : 3758-3762.
PubMed
65) Morita S, et al. : Graves' disease associated with goserelin acetate. Acta Med Nagasaki 2002 ; 47 : 79-80.
 
66) Amino N, et al. : Postpartum autoimmune thyroid syndrome. Endocr J 2000 ; 47 : 645-655.
PubMed
67) Marqusee E, et al. : The effect of droloxifene and estrogen on thyroid function in postmenopausal women. J Clin Endocrinol Metab 2000 ; 85 : 4407-4410.
PubMed
68) Glinoer D, et al. : Stimulation of thyroxine-binding globulin synthesis by isolated rheusus monkey hepatocytes after in vivo beta-estradiol administration. Endocrinol 1977 ; 100 : 807-813.
 
69) Beex L, et al. : 5-Fluorouracil-induced increase of total serum thyroxine and triiodothyronine. Cancer Treat Rep 1977 ; 61 : 1291-1295.
PubMed
70) Badros AZ, et al. : Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 2002 ; 112 : 412-413.
PubMed
71) de Savary N, et al. : Severe hypothyroidism after thalidomide treatment. J RoyalSoc Med 2004 ; 97 : 443.
 
72) Erdem F, et al. : Autoimmune thyroiditis during thalidomide treatment. Am J Hematol 2006 ; 81 : 152.
PubMed
73) Figaro MK, et al. : Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies : results of a retrospective case review. Am J Hematol 2011 ; 86 : 467-470.
PubMed
74) Iams WT, et al. : Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism. Exp Hematol 2015 ; 43 : 74-78.
 
社団法人日本甲状腺学会マニュアル作成委員会, ほか : 重篤副作用疾患別対応マニュアル 甲状腺機能低下症 平成21年5月 (令和4年2月改定). 厚生労働省, 2022. https://www.mhlw.go.jp/topics/2006/11/d1/tp1122-ld37.pdf (2022年4月27日アクセス)
 
Skelin M, et al. : Factors Affecting Gastrointestinal Absorption of Levothyroxine : A Review. Clin Ther 2017 ; 39 : 378-403.
PubMed
DrugBank Online : Database for Drug and Drug Target Info. https://go.drugbank.com (2022年5月12日アクセス)
 
P.51 掲載の参考文献
1) 山本竜大, ほか : ステロイドの種類・使い分け・相互作用. 臨と研 2011 ; 88 : 1-5
 
2) Denny N, et al. : Rifampicin-induced adrenal crisis in a patient with tuberculosis: a therapeutic challenge. BMJ Case Rep 2016 ; 2016 : bcr2016216302
 
3) Santhana Krishnan SG, et al. : Reversible acute adrenal insufficiency caused by fluconazole in a critically ill patient. Postgrad Med J 2006 ; 82 : e23.
 
4) Barroso-Sousa R, et al. : Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol 2018 ; 4 : 173-182
 
P.53 掲載の参考文献
1) 社団法人日本内分泌学会マニュアル (第二版) 作成委員会, ほか : 重篤副作用疾患別対応マニュアル 偽アルドステロン症 平成18年11月 (令和4年2月改定). 厚生労働省, 2022. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1d29.pdf (2022年4月27日アクセス)
 
2) Sigurjonsdottir HA, et al. : Liquorice-induced rise in blood pressure : a linear dose-response relationship. J Hum Hypertens 2001 ; 15 : 549.
PubMed
3) 本間真人, ほか : 芍薬甘草湯と小柴胡湯の連用が血清カリウム値に及ぼす影響. YAKUGAKU ZASSHI 2006 ; 126 : 973-978.
Medical*Online
4) 本間真人 : 漢方薬の副作用と安全性. 薬事 2011 ; 53 : 1725-1729.
Medical*Online
5) 使用上の注意の改訂について (その254). 医薬品・医療機器等安全性情報 2014 ; 311 : 14-15. https://www.mhlw.go.jp/www1/kinkyu/iyaku_j/iyaku_j/anzenseijyouhou/311_3.pdf (2021年5月25日アクセス)
 

各論 ( 薬効別 )

P.65 掲載の参考文献
1) Molitch ME : Drugs and prolactin. Pituitary 2008 ; 11 : 209-218.
PubMed
2) Dreijerink KM, et al. : Atypical Hypocortisolism. Endocr Pract 2013 ; 19 : e112-e114.
 
3) Lazarus JH : Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009 ; 23 : 723-733.
PubMed
4) McKnight RF, et al. : Lithium toxicity profile : a systematic review and meta-analysis. Lancet 2012 ; 379 : 721-728.
PubMed
5) Wilkinson TJ, et al. : Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. Br J Clin Pharmacol 1999 ; 47 : 211-217.
PubMed
6) 関原久彦 : 薬物によるコルチゾールおよび合成糖質コルチコイドの代謝促進作用. 日内会誌 1992 ; 81 : 490-493.
 
7) Shih FY, et al. : Effects of antiepieptic drugs on thyroid hormone function in epilepsy patients. Seizure 2017 ; 48 : 7-10.
 
8) Patil MM, et al. : Phenytoin Induced Osteopathy Too Common to be Neglected. J Clin Diagn Res 2015 ; 9 : OD11-OD12.
PubMed
9) Hoikka V, et al. : Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scand 1981 ; 64 : 122-131.
PubMed
10) Dahiya K, et al. : Phenytoin Monotherapy in Epilepsy and its Effect on TSH. Int J Pharm Sci Res 2016 ; 48 : 4656-4659.
 
11) Fernandez H, et al. : Vitamin D supplementation for bone health in adults with epilepsy : A systematic review. Epilepsia 2018 ; 59 : 885-896.
PubMed
12) Kuz GM, et al. : Carbamazepine-induced hyponatremia : assessment of risk factors. Ann Pharmacother 2005 ; 39 : 1943-1946.
PubMed
13) O'Hare JA, et al. : Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand 1980 ; 62 : 282-286.
PubMed
14) 須藤章, ほか : カルバマゼピン服用者の低ナトリウム血症について. 日小児会誌 2001 ; 105 : 755-762.
 
15) Kafadar I, et al. : Evaluation of Thyroid Hormones in Children Receiving Carbamazepine or Valproate : a Prospective Study. J Child Neurol 2015 ; 30 : 63-68.
PubMed
16) Gungor O, et al. : The effect of antiepileptic drugs on thyroid hormonal function : valproic acid and phenobarbital. Acta Neurol Belg 2020 ; 120 : 615-619.
PubMed
17) Lai EC, et al. : Use of antiepileptic drugs and risk of hypothyroidism. Pharmacoepidemiol Drug Saf 2013 ; 22 : 1071-1079.
PubMed
18) 川合眞一 : ステロイド内服薬の選び方・使い方. アレルギー 2009 ; 58 : 7-12.
Medical*Online
19) 田渕優希子, ほか : オピオイドによる内分泌機能異常. 日ペインクリニック会誌 2013 ; 20 : 17-23.
Medical*Online
20) Gudin JA, et al. : Opioid related endocrinopathy. Pain Med 2015 ; 16 Supply 1 : S9-S15.
 
21) Brennan MJ : The effect of opioid therapy on endocrine function. Am J Med 2013 ; 126 (3 Supply 1) : S12-S18.
 
22) Albert SG, et al. : The effect of etomidate on adrenal function in critical illness : a systematic review. Intensive Care Med 2011 ; 37 : 901-910.
PubMed
23) Molenaar N, et al. : Steroidogenesis in the adrenal dysfunction of critical illness : impact of etomidate. Crit Care 2012 ; 16 : R121.
PubMed
24) 河手久弥, ほか : 副腎皮質機能低下症を早期診断・治療するために. 日内会誌 2014 ; 103 : 878-885.
 
P.68 掲載の参考文献
1) Molitch ME : Drugs and prolactin. Pituitary 2008 ; 11 : 209-218.
PubMed
2) Spitzer M, et al. : Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol 1998 ; 91 : 693-695.
PubMed
3) Melmed S, et al. : Diagnosis and treatment of hyperprolactinemia : an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011 ; 96 : 273-288.
PubMed
4) Ehrinpreis MN, et al. : Cimetidine-induced galactorrhea. Am J Gastroenterol 1989 ; 84 : 563-365.
PubMed
5) Burland WL, et al. : Prolactin responses to cimetidine. Br J Clin Pharmacol 1979 ; 7 : 19-21.
 
6) Rampello L, et al. : Neurobehavioral syndrome induced by H2-receptor blocker withdrawal : possible role of prolactin. Clin Neuropharmacol 1997 ; 20 : 49-54.
PubMed
7) Carlson HE, et al. : Effect of cimetidine on serum prolactin in normal women and patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1981 ; 15 : 491-498.
PubMed
8) Spona J, et al. : Effects of low and high dose oral cimetidine on hormone serum levels in patients with peptic ulcers. Endocrinol Exp 1987 ; 21 : 149-157.
PubMed
9) Melmed S, et al. : Diagnosis and treatment of hyperprolactinemia : an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011 ; 96 : 273-288.
PubMed
10) 社団法人日本甲状腺学会マニュアル作成委員会, ほか : 重篤副作用疾患別対応マニュアル 甲状腺機能低下症 平成21年5月 (令和4年2月改定). 厚生労働省, 2022. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1d37.pdf (2022年5月20日アクセス)
 
11) Liamis G, et al. : A review of drug-induced hyponatremia. Am J Kidney Dis 2008 ; 52 : 144-153.
PubMed
12) Centanni M, et al. : Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006 ; 354 : 1787-1795.
PubMed
13) Brewster UC, et al. : Proton pump inhibitors and the kidney : Critical review. Clin Nephrol 2007 ; 68 : 65-72.
PubMed
14) Falhammar H, et al. : Associations of proton pump inhibitors and hospitalization due to hyponatremia : A population-based case-control study. Eur J Intern Med 2019 ; 59 : 65-69.
 
15) 鈴木聡, ほか : H.pylori除菌中にSIADHを発症した1例. 日内会誌 2012 ; 101 : 1393-1396.
 
16) Sachmechi I, et al. : Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract 2007 ; 13 : 345-349.
PubMed
17) Ananthakrishnan S, et al. : The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid 2008 ; 18 : 493-498.
PubMed
P.72 掲載の参考文献
1) 西川光重 : 薬剤による甲状腺障害. 日内会誌 2010 ; 99 : 776-785.
 
2) 社団法人日本甲状腺学会マニュアル作成委員会, ほか : 重篤副作用疾患別対応マニュアル 甲状腺機能低下症 平成21年5月 (令和4年2月改定). 厚生労働省, 2022. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1d37.pdf (2022年5月20日アクセス)
 
3) 社団法人日本甲状腺学会マニュアル作成委員会, ほか : 重篤副作用疾患別対応マニュアル 甲状腺中毒症 平成21年5月 (令和4年2月改定). 厚生労働省, 2022. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1d33.pdf (2022年5月30日アクセス)
 
4) Persani L, et al. : Central hypothyroidism. In : Braverman LE, et al. (eds) : Werner & Ingbar's The Thyroid, 11th ed. Lippincott Williams & Wilkins, 2021 ; 566-574.
 
5) Chadha C, et al. : Effect of epoprostenol on the thyroid gland : enlargement and secretion of thyroid hormone. Endocr Pract 2009 ; 15 : 116-121.
PubMed
6) Satoh M, et al. : Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension. Endocr J 2017 ; 64 : 1173-1180.
PubMed
7) Melmed S, et al. : Diagnosis and Treatment of Hyperprolactinemia : An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011 ; 96 : 273-288.
PubMed
8) Molitch ME : Medication-induced Hyperprolactinemia. Mayo Clin Proc 2005 ; 80 : 1050-1057.
PubMed
9) Barbieri C, et al. : Endocrine and metabolic effects of labetalol in men. J Cardiovasc Pharmacol 1981 ; 3 : 986-991.
 
10) Barbieri C, et al. : Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system. Clin Endocrinol (Oxf) 1982 ; 16 : 615-619.
PubMed
P.81 掲載の参考文献
1) Hahner S, et al. : Adrenal insufficiency. Nat Rev Dis Primers 2021 ; 7 : 19.
 
2) Lauge sen K, et al. : MANAGEMENT OF ENDOCRINE DISEASE : Glucocorticoid-induced adrenal insufficiency : replace while we wait for evidence? Eur J Endocrinol 2021 ; 184 : R111-R122.
 
3) Yanase T, et al. : Diagnosis and treatment of adrenal insufficiency including adrenal crisis : a Japan Endocrine Society clinical practice guideline［ Opinion］. Endocr J 2016 ; 63 : 765-784.
PubMed
4) Kapadia CR, et al. : Endocrine Effects of Inhaled Corticosteroids in Children. JAMA Pediatr 2016 ; 170 : 163-170.
PubMed
5) 西川光重 : 薬剤による甲状腺障害. 日内会誌 2010 ; 99 : 94-103.
 
6) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編) : 高血圧治療ガイドライン 2019. ライフサイエンス出版, 2019 : 193-197.
 
7) 日本泌尿器科学会 (編) : 前立腺癌診療ガイドライン 2016年版. メディカルレビュー社, 2016 : 214-218.
 
8) ヒスロン(R) H 錠200 mg (医薬品インタビューフォーム) , 2022年3月改訂 (第2版), 協和キリン, 2022 : 24-25. https://medical.kyowakirin.co.jp/site/drugpdf/interv/hys_h_in.pdf (2022年5月アクセス)
 
9) Sasagawa S, et al. : Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008 ; 73 : 222-231.
PubMed
10) サンドスタチン(R) LAR(R) 筋注用キット (医薬品インタビューフォーム) , 2020年8月改訂 (第4版) , ノバルティスファーマ, 2015. http://www.info.pmda.go.jp/go/interview/1/300242_2499403A1037_1_SAS_1F.pdf (2022年5月アクセス)
 
11) ソマチュリン(R) 皮下注 (医薬品インタビューフォーム) , 2020年12月改訂 (第5版) , 帝人ファーマ, 2020. https://www.info.pmda.go.jp/go/interview/1/470310_2499413G1025_1_007_1F.pdf (2022年5月アクセス)
 
12) シグニフォー(R) LAR(R) 筋注用キット (医薬品インタビューフォーム) , 2020年6月改訂 (第3版) , レコルダティ・レア・ディジーズ・ジャパン, 2020. https://www.info.pmda.go.jp/go/interview/2/870276_2499417G1023_2_002_1F.pdf (2021年8月アクセス)
 
13) Kuhn JM, et al. : Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmac 1994 ; 38 : 213-219.
 
14) Haugen BR : Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab 2009 ; 23 : 793-800.
PubMed
P.83 掲載の参考文献
1) Moses AM, et al. : Clofibrate-induced antidiuresis. J Clin Invest 1973 ; 52 : 535-542.
PubMed
2) Thompson P Jr, et al. : Comparison of clofibrate and chlorpropamide in vasopressin-responsive diabetes insipidus. Metabolism 1977 ; 26 : 749-762.
PubMed
3) Rado JP, et al. : Dose-response relations in drug-induced inappropriate secretion of ADH : effects of clofibrate and carbamazepine. Int J Clin Pharmacol Biopharm 1975 ; 12 : 315-319.
PubMed
4) Makaryus AN, et al. : Diabetes insipidus : diagnosis and treatment of a complex disease. Cleve Clin J Med 2006 ; 73 : 65-71.
PubMed
5) Northcutt RC, et al. : The influence of cholestyramine on thyroxine absorption. JAMA 1969 ; 208 : 1857-1861.
PubMed
6) Kaykhaei MA, et al. : Low doses of cholestyramine in the treatment of hyperthyroidism. Endocrine 2008 ; 34 : 52-55.
PubMed
7) 日本内分泌学会, ほか : 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日内分泌会誌 2015 ; 91 (Suppl) : 1-78.
 
8) Nowak SN, et al. : Pioglitazone : effect on CYP3A4 activity. J Clin Pharmacol 2002 ; 42 : 1299-1302.
PubMed
9) Marqusee E, et al. : The effect of droloxifene and estrogen on thyroid function in postmenopausal women. J Clin Endocrinol Metab 2000 ; 85 : 4407-4410.
PubMed
10) Zamfirescu I, et al. : Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid 2011 ; 21 : 483-486.
PubMed
11) Skelin M, et al. : Factors Affecting Gastrointestinal Absorption of Levothyroxine : A Review. Clin Ther 2017 ; 39 : 378-403.
PubMed
12) Singh N, et al. : Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000 ; 283 : 2822-2825.
PubMed
P.90 掲載の参考文献
1) Antonelli A, et al. : Thyroid disorders in chronic hepatitis C. Am J Med 2004 ; 117 : 10-13.
PubMed
2) Shen Y, et al. : Thyroid Disturbance in Patients with Chronic Hepatitis C Infection : A Systematic Review and Meta-analysis. J Gastrointestin Liver Dis 2016 ; 25 : 227-234.
PubMed
3) Blackard JT, et al. : Hepatitis C virus infection of a thyroid cell line : implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid 2013 ; 23 : 863-870.
PubMed
4) Piantanida E, et al. : The interplay between thyroid and liver : implications for clinical practice. J Endocrinol Invest 2020 ; 43 : 885-899.
PubMed
5) Parsa AA, et al. : HIV and thyroid dysfunction. Rev Endocr Metab Disord 2013 ; 14 : 127-131.
PubMed
6) Chen F, et al. : Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore) 2005 ; 84 : 98-106.
PubMed
7) Tola HH et al. : Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis. PLoS One 2019 ; 14 : e0218487.
PubMed
8) Kyriazopoulou V, et al. : Abnormal overnight dexamethasone suppression test in subjects receiving rifampicin therapy. J Clin Endocrinol Metab 1992 ; 75 : 315-317.
PubMed
9) Kim HI, et al. : Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine Medication. PLoS One 2017 ; 12 : e0169775.
PubMed
10) Munivenkatappa S, et al. : Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis : Notes from the Field. J Tuberc Res 2016 ; 4 : 105-110.
 
11) Thee S, et al. : Abnormal thyroid function tests in children on ethionamide treatment. Int J Tuberc Lung Dis 2011 ; 15 : 1191-1193, i.
PubMed
12) Dutta BS, et al. : Ethionamide-induced hypothyroidism. Int J Tuberc Lung Dis 2012 ; 16 : 141.
PubMed
13) Lionakis MS, et al. : Endocrine and metabolic manifestations of invasive fungal infections and systemic antifungal treatment. Mayo Clin Proc 2008 ; 83 : 1046-1060.
PubMed
14) Boyd AE, et al. : Adverse reactions to voriconazole. Clin Infect Dis 2004 ; 39 : 1241-1244.
PubMed
15) Sonino, N : The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987 ; 317 : 812-818.
PubMed
16) Skov M, et al. : Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002 ; 20 : 127-133.
PubMed
17) Vidal-Puig AJ, et al. : Ketoconazole therapy : hormonal and clinical effects in non-tumoral hyperandrogenism. Eur J Endocrinol 1994 ; 130 : 333-338.
PubMed
18) Einstein MH, et al. : Comparative immunogenicity and safety of human papillomavirus ( HPV) -16/18 vaccine and HPV-6/11/16/18 vaccine : follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011 ; 7 : 1343-1358.
 
19) Willame C, et al. : Systematic Review and Meta-analysis of Postlicensure Observational Studies on Human Papillomavirus Vaccination and Autoimmune and Other Rare Adverse Events. Pediatr Infect Dis J 2020 ; 39 : 287-293.
PubMed
20) Chao C, et al. : Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012 ; 271 : 193-203.
PubMed
21) Yoon D, et al. : Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls : nationwide cohort study. BMJ 2021 ; 372 : m4931.
PubMed
22) Human papillomavirus vaccines : WHO position paper, May 2017. Wkly Epidemiol Rec 2017 ; 92 : 241-268.
PubMed
P.94 掲載の参考文献
1) Moncoucy X, et al. : Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 2005 ; 29 : 339-345.
PubMed
2) Tomer Y, et al. : Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 2009 ; 23 : 703-712.
PubMed
3) Bhattacharya S, et al. : Anticancer Drug-induced Thyroid Dysfunction. Eur Endocrinol 2020 ; 16 : 32-39.
PubMed
4) 社団法人日本甲状腺学会マニュアル作成委員会, ほか : 重篤副作用疾患別対応マニュアル 甲状腺機能低下症 平成21年5月 (令和4年2月改定). 厚生労働省, 2022. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1d37.pdf (2022年5月20日アクセス)
 
5) Ward DL, et al. : Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C : screening and monitoring recommendations. Endocr Pract 2001 ; 7 : 52-58.
PubMed
6) Fehniger TA, et al. : Inter leukin-2 and inter leukin-15 : immunotherapy for cancer. Cytokine Growth Factor Rev 2002 ; 13 : 169-183.
 
7) Krouse RS, et al. : Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 1995 ; 18 : 272-278.
PubMed
8) Curti B, et al. : Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events : data from the PROCLAIM(SM) registry. J Immunother Cancer 2017 ; 5 : 102.
PubMed
9) Bhattacharya S, et al. : Anticancer Drug-induced Thyroid Dysfunction. Eur Endocrinol 2020 ; 16 : 32-39.
PubMed
10) Shin JI, et al. : Development of Graves' disease during cyclosporin treatment for severe Henoch?Schonlein nephritis. Nephrol Dial Transplant 2005 ; 20 : 2014-2015.
PubMed
11) Iwasaki H : Onset of Graves ' di sease dur ing long-term immunosuppressive therapy in a patient with membranous nephropathy. Endocrinol Diabetes Metab Case Rep 2015 ; 2015 : 150046.
 
12) Hofle G, et al. : Endocrine ophthalmopathy in a patient under continuous immunosuppressive therapy after cardiac transplantation. Thyroid 1995 ; 5 : 477-480.
 
13) Sakaguchi N, et al. : Causes and mechanism of autoimmune disease : cyclosporin A as a probe for the investigation. J Invest Dermatol 1992 ; 98 ( 6 Suppl) : 70S-76S.
 
14) Fournier C, et al. : In vivo beneficial effects of cyclosporin A and 1,25-dihydroxyvitamin D3 on the induction of experimental autoimmune thyroiditis. Clin Immunol Immunopathol 1990 ; 54 : 53-63.
PubMed
15) Hassman RA, et al. : The influence of cyclosporin A on the induction of experimental autoimmune thyroid disease in the PVG/c rat. Clin Exp Immunol 1985 ; 59 : 10-16.
PubMed
P.110 掲載の参考文献
1) Makita N, et al. : Tyrosine kinase inhibitor-induced thyroid disorders : a review and hypothesis. Thyroid 2013 ; 23 : 151-159.
PubMed
2) Ahmadieh H, et al. : Tyrosine kinase inhibitors induced thyroid dysfunction : A review of its incidence, pathophysiology, clinical relevance, and treatment. Biomed Res Int 2013 ; 2013 : 725410.
PubMed
3) Bilgir O, et al. : Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction? Int J Clin Pract 2010 ; 64 : 45-50.
PubMed
4) Colombo C, et al. : Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy. J Clin Endocrinol Metab 2019 ; 104 : 779-784.
PubMed
5) Elshimy G, et al. : Tyrosine Kinase Inhibitors' Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer. J Investig Med High Impact Case Rep 2020 ; 8 : 2324709620936808.
 
6) Rock EP, et al. : Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007 ; 12 : 107-113.
PubMed
7) Lodish MB : kinase inhibitors : adverse effects related to the endocrine system. J Clin Endocrionl Metab 2013 ; 98 : 1333-1342.
 
8) Weickhardt AJ, et al. : Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer 2013 ; 119 : 2383-2390.
PubMed
9) Mannavola D, et al. : A novel tyrosine-kinase selective inhibitor, Sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrionl Metab 2007 ; 92 : 3531-3534.
 
10) Postow MT, et al. : Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018 ; 378 : 158-168.
PubMed
11) Barroso-Sousa R, et al. : Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens : A systematic Review and Meta-Analysis. JAMA Oncol 2018 ; 4 : 173-182.
PubMed
12) Iwama S, et al. : Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014 ; 6 : 230ra45.
PubMed
13) Takahashi Y. : MECHANISMS IN ENDOCRINOLOGY : Autoimmune hypopituitarism : novel mechanistic inshights. Eur J Endocrinol 2020 ; 182 : R59-R66.
 
14) Kanie K, et al. : Mechanistic insights into immune checkpoint inhibitor-related hypophysitis : a form of paraneoplastic syndrome. Cancer Immunol Immunother 2021 : 70 : 3669-3677.
PubMed
15) Yasuda Y, et al. : CD4＋ T cell are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci Transl Med 2021 ; 13 : eabb7495.
PubMed
16) 日本内分泌学会 : 免疫チェックポイント阻害薬による内分泌障害の診療ガイドライン. 日内分泌会誌 2018 ; 94 (Suppl) : 1-11.
 
17) 社団法人日本甲状腺学会マニュアル作成委員会, ほか : 重篤副作用疾患別対応マニュアル 甲状腺中毒症 平成21年5月 (令和4年2月改定). 厚生労働省, 2022. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1d33.pdf (2022年5月30日アクセス)
 
18) 馬殿恵, ほか : 抗PD-1抗体投与後に発症する1型糖尿病の特徴および臨床経過に関する調査報告. 糖尿病 2019 ; 62 : 37-46.
 
19) Levin L, et al. : Syndrome of inappropriate antidiuretic hormone secretion following dis-dichlorodiammineplatinum II in a patient with malignant thymoma. Cancer 1982 ; 50 : 2279-2282.
 
20) Hatakeyama S, et al. : Risk Factors for Severe Hyponatremia Related to Cisplatin : A Retrospective Case-Control Study. Biol Pharm Bull 2019 ; 42 : 1891-1897.
PubMed
21) Reyad D, et al. : Hyponatremia and SIADH Frequency in Clinically Euvolemic Patients Receiving Chemotherapy: Prospective Study in Unselected Patients' Cohort. J Cancer Sci Ther. 2016 ; 8 : 55-58.
 
22) 内田洋一朗, ほか : CDDPが誘因と考えられたSIADHを発症した消化器癌FP療法の2例. 日消外会誌 2004 : 37 : 1588-1593.
 
23) Castillo JJ, et al. : Diagnosis and management of hyponatremia in cancer patients. Oncologist 2012 ; 17 : 756-765.
PubMed
24) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班 (編) : バソプレシン分泌過剰症 (SIADH) の診断と治療の手引き. 間脳下垂体機能障害の診断と治療の手引き (平成30年度改訂). 日内分泌会誌 2019 : 95 (Suppl.) ; 18-20. https://www.jstage.jst.go.jp/article/endocrine/95/S.May/95_1/_pdf/-char/ja (2022年5月31日アクセス)
 
25) Fine RN, et al. : Hyponatremia and vincristine therapy. Syndrome possibly resulting from inappropriate antidiuretic hormone secretion. Am J Dis Child 1966 ; 112 : 256-259.
PubMed
26) Hammond IW, et al. : Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine : an over-representation of Asians? Pharmacoepidemiol Drug Saf 2002 ; 11 : 229-234.
PubMed
27) 吉田尚, ほか : 抗利尿ホルモン分泌異常症. 日本臨牀 1987 ; 45 (夏季増刊) : 852-858.
Medical*Online
28) Stuart MJ, et al. : Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of Vincristine. Blood 1975 ; 45 : 315-320.
PubMed
29) Nagappa M, et al. : Vincristine-induced acute life-threatening hyponatremia resulting in seizure and coma. Indian J Crit Care Med 2009 ; 13 : 167-168.
PubMed
30) Beex L, et al. : 5-fluorouracil-induced increase of total serum thyroxine and triiodothyronine. Cancer Treat Rep 1977 ; 61 : 1291-1295.
PubMed
31) 社団法人日本甲状腺学会マニュアル作成委員会, ほか : 重篤副作用疾患別対応マニュアル 甲状腺機能低下症 平成21年5月 (令和4年2月改定). 厚生労働省, 2022. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1d37.pdf (2022年5月31日アクセス)
 
32) Ain KB, et al. : Relationship of oligosaccharide modification to the cause of serum thyroxine-binding globulin excess. J Clin Endocrinol Metab 1988 ; 66 : 1037-1043.
 
33) Fujiwara Y, et al. : Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines. Oncol Rep 2013 ; 30 : 1802-1806.
PubMed
34) 上條桂一, ほか : 癌患者における内分泌環境異常と抗癌剤の影響. 癌と化学療法 1987 ; 14 : 755-762.
Medical*Online
35) Narula HS, et al. : Capecitabine-induced abnormalities in thyroid function tests. Am J Med 2004 ; 116 : 855-856.
PubMed
36) Siraj ES, et al. : Raloxifene causing malabsorption of levothyroxine. Arch Intern Med 2003 ; 163 : 1367-1370.
PubMed
37) 西川光重 : 薬剤による甲状腺障害. 日内会誌 2010 ; 99 : 776-785.
 
38) Mamby CC, et al. : Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J Clin Oncol 1995 ; 13 : 854-857.
PubMed
39) Ceresini G, et al. : A one-year follow-up on the effects of raloxifene on thyroid function in postmenopausal women. Menopause 2004 ; 11 : 176-179.
PubMed
40) McKeand WE, et al. : A double-blind, randomized, ascending, multiple-dose study of bazedoxifene in healthy postmenopausal women. Clin Pharmacol Drug Dev 2014 ; 3 : 262-269.
PubMed
41) Badros AZ, et al. : Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 2002 ; 112 : 412-413.
PubMed
42) Hamnvik OP, et al. : Thyroid Dysfunction from Antineoplastic Agents. J Natl Cancer Inst 2011 ; 103 : 1572-1587.
PubMed
43) Iams WT, et al. : Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism. Exp Hematol 2015 ; 43 : 74-78.
 
44) Ali SH, et al. : Pomalidomide-induced hypothyroidism. Endocrinol Diabetes Metab Case Rep 2017 ; 2017 : 17-0110.
PubMed
45) Bhattacharya S, et al. : Anticancer Drug-induced Thyroid Dysfunction. Eur Endocrinol 2020 ; 16 : 32-39.
PubMed
P.112 掲載の参考文献
Conn JW, et al. : Licorice-induced pseudoaldosteronism. Hypertension, hypokalemia, aldosteronopenia, and suppressed plasma renin activity. JAMA 1968 ; 205 : 492-496.
PubMed
社団法人日本内分泌学会マニュアル (第二版) 作成委員会, ほか : 重篤副作用疾患別対応マニュアル 偽アルドステロン症 平成18年11月 (令和4年2月改定). 厚生労働省, 2022 https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1d29.pdf (2022年3月22日アクセス)
 

書評

最近チェックした商品履歴

Loading...